Summary
CVS Health Corp (CVS) reported its third-quarter 2010 results, showing a slight decrease in net revenues compared to the prior year. This was primarily driven by the termination of large client contracts and a decrease in Medicare Part D covered lives within the Pharmacy Services segment, partially offset by growth in the Retail Pharmacy segment from same-store sales and new store openings. Profitability saw a mixed performance. While gross profit dollars remained relatively stable, gross profit margins experienced slight pressure in the Pharmacy Services segment due to regulatory changes and competitive pricing, while the Retail Pharmacy segment saw a marginal improvement in gross profit margin. Operating expenses increased, largely due to higher store operating costs and litigation expenses. Diluted earnings per share for the quarter also saw a decline compared to the prior year. Investors should note the ongoing legal proceedings and regulatory investigations, particularly those related to government claims processing and controlled substances, which represent potential future risks.
Financial Highlights
57 data points| Revenue | $23.71B |
| Cost of Revenue | $18.70B |
| Gross Profit | $5.01B |
| Operating Expenses | $3.54B |
| Operating Income | $1.48B |
| Interest Expense | $138.00M |
| Net Income | $809.00M |
| EPS (Basic) | $0.59 |
| EPS (Diluted) | $0.59 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.37B |
Key Highlights
- 1Net revenues for the three months ended September 30, 2010, decreased by 3.1% to $23.875 billion compared to $24.642 billion in the prior year period.
- 2Pharmacy Services segment net revenues decreased by 8.5% to $11.926 billion, impacted by contract terminations and reduced Medicare Part D lives.
- 3Retail Pharmacy segment net revenues increased by 4.1% to $14.159 billion, driven by same-store sales growth and new store openings.
- 4Diluted earnings per common share attributable to CVS Caremark decreased to $0.59 for the three months ended September 30, 2010, from $0.71 in the prior year period.
- 5The company repurchased approximately $1.5 billion of its common stock in the first six months of 2010, completing its $2.0 billion 2009 Repurchase Program, and authorized a new $2.0 billion repurchase program in June 2010.
- 6Significant ongoing legal proceedings and government investigations are disclosed, including a $75 million civil penalty resolution with the DEA related to pseudoephedrine distribution.